Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Morgan Stanley    MS

MORGAN STANLEY

(MS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Morgan Stanley : rates CSL as Equal-weight

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2020 | 06:31pm EDT

Morgan Stanley suspects the risks associated with coronavirus are manageable. The main source of risk is lower plasma collections.

CSL sources plasma in the US and EU where implementation of containment measures could lead to reduced volumes. However, the broker assesses no impact in FY20 and only a small impact to FY21, with -8-24% downside to FY20 to earnings.

Equal-weight maintained. Target is raised to $260 from $258. In-Line sector view retained.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $260.00.Current Price is $270.88. Difference: ($10.88) - (brackets indicate current price is over target). If CSL meets the Morgan Stanley target it will return approximately -4% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MORGAN STANLEY
05/24MORGAN STANLEY : rates ECX as Equal-weight
AQ
05/24MORGAN STANLEY : rates WES as Equal-weight
AQ
05/22MORGAN STANLEY : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/22JUST EAT TAKEAWAY.COM : Morgan Stanley reaffirms its Buy rating
MD
05/22SCOUT24 : Morgan Stanley remains Neutral
MD
05/22Why bond investors are willing to bet on money-losing Pemex after oil price c..
RE
05/22Banks pursue Luckin Coffee chairman's assets after loan default
RE
05/21KKR to Invest $1.5 Billion in Reliance's Jio Platforms
DJ
05/21Utilities Down As Traders Step Back From a Fast-Rising Sector -- Utilities Ro..
DJ
05/21Health Care Down On Cyclical Bias -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2020 36 365 M
EBIT 2020 7 596 M
Net income 2020 5 414 M
Debt 2020 118 B
Yield 2020 3,53%
P/E ratio 2020 11,2x
P/E ratio 2021 9,06x
EV / Sales2020 5,00x
EV / Sales2021 4,52x
Capitalization 63 231 M
Chart MORGAN STANLEY
Duration : Period :
Morgan Stanley Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MORGAN STANLEY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 47,42 $
Last Close Price 40,13 $
Spread / Highest target 54,5%
Spread / Average Target 18,2%
Spread / Lowest Target -10,3%
EPS Revisions
Managers
NameTitle
James Patrick Gorman Chairman & Chief Executive Officer
Jonathan M. Pruzan Chief Financial Officer & Executive Vice President
Robert Rooney Head-Technology, Operations & Firm Resilience
Hutham S. Olayan Independent Director
Robert H. Herz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MORGAN STANLEY-21.50%63 231
THE GOLDMAN SACHS GROUP, INC.-21.75%64 520
THE CHARLES SCHWAB CORPORATION-30.97%42 266
CITIC SECURITIES COMPANY LIMITED-12.21%37 222
CSC FINANCIAL CO., LTD.2.98%29 676
HUATAI SECURITIES CO., LTD.-14.57%20 281